Targeted Medical Pharma, Inc . (OTCQB:TRGM), reported today on the completion of an independent sales agreement with Pacific Medical, Inc., a distributor of durable medical equipment in the United States who specializes in orthopedic, rehabilitation, surgery and sports medicine.
The non-exclusive agreement will allow Targeted Medical Pharma to expand medical food sales and education programs to licensed healthcare professionals in Northern California and Northern Nevada for an initial period of one year. The programs will focus on educating prescribers who are currently treating patients with sleep, pain , obesity , and cognitive disorders about safe, effective, non-narcotic medical food treatment options.
"Pacific Medical is another important new business partner of Targeted Medical Pharma, we are very pleased with the sales contract and believe that Pacific Medical’s stellar reputation for delivering quality products and education programs will help healthcare providers understand the importance of utilizing our medical food products as a first line therapy for mitigating pain and inflammation without the risks associated with narcotic pain medications,” said William Shell, M.D. CEO and Chief Science Officer of Targeted Medical Pharma, Inc. “We believe that Pacific Medical will help enhance the quality of our sales and education program and increase our market penetration with orthopedic and sports medicine specialists.”
About Targeted Medical Pharma, Inc.
Targeted Medical Pharma, Inc . is a Los Angeles-based biotechnology company that develops medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™. The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.
Forward Looking Statement
This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.
